Clinical trial
Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did…
NCT00337077 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00337077 |
|---|---|
| Title | Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy |
| Official title | A Phase II Trial of E7389 (Halichondrin B Analog), in Patients With Metastatic Hormone Refractory Prostate Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of the Prostate, Hormone-refractory Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer |
| Intervention type | Drug |
| Interventions | eribulin mesylate |
| Enrollment | 121 |
| Start date | Nov 1, 2006 |
| Primary completion | Jun 1, 2009 |
| Completion | Nov 1, 2013 |
| First posted | Jun 15, 2006 |
| Last update posted | Jun 23, 2014 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: